Glioblastoma multiforme (GBM) remains one of the most aggressive adult brain tumours, with median survival rarely exceeding 15 months. Yet a subset of patients—often classified as long-term ...
Genenta Science has announced that 38 patients have been enrolled in its study for newly diagnosed glioblastoma multiforme (GBM), where 25 patients received the treatment Temferon. Two patients have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results